Bayer AG ((BAYRY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Bayer AG is conducting an observational study titled ‘Finerenone Research of Outcomes and Drug Utilization’ (FINEROD) to assess the real-world use, safety, and efficacy of finerenone in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). This study is significant as it aims to gather data on the characteristics of patients using finerenone, a newly approved drug in the US, and its impact on kidney and heart health.
Intervention/Treatment: The study focuses on finerenone, a drug that blocks mineralocorticoid receptors to potentially reduce damage to kidneys, heart, and blood vessels. It is administered in doses of 10 mg or 20 mg daily to patients with CKD and T2D.
Study Design: This is a retrospective cohort observational study, meaning it looks back at existing data from electronic health records and national claims in the US and Asia. There are no new interventions or visits required, as the study only collects and analyzes existing data.
Study Timeline: The study began collecting data on February 9, 2024, with the latest update submitted on September 15, 2025. These dates are crucial for tracking the progress and currency of the data being analyzed.
Market Implications: The ongoing study could influence Bayer’s stock performance positively by providing insights into finerenone’s effectiveness and safety, potentially boosting investor confidence. As finerenone competes in the CKD and T2D treatment market, successful outcomes could enhance Bayer’s competitive edge.
The study is currently recruiting, with further details available on the ClinicalTrials portal.